Gujarat-based manufacturer of pharmaceutical, nutraceutical, herbal and Ayurvedic products, with commercial production commenced in December 2020.
Price
Market Cap
Sector
Healthcare
Rank
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | FY26 |
|---|---|---|---|---|---|---|---|
| LiabilitiesEquity Capital | 3 | 5 | 5 | 5 | 9 | 9 | 9 |
| Reserves | 1 | 6 | 7 | 9 | 7 | 8 | 10 |
| Borrowings | 7 | 7 | 10 | 8 | 8 | 8 | 17 |
| Other Liabilities | 6 | 10 | 12 | 15 | 23 | 28 | 30 |
| Total Liabilities | 18 | 28 | 34 | 37 | 47 | 54 | 66 |
| AssetsFixed Assets | 2 | 2 | 10 | 10 | 11 | 11 | 12 |
| CWIP | 1 | 4 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 2 | 2 | 2 | 3 |
| Other Assets | 15 | 21 | 24 | 25 | 35 | 40 | 51 |
| Total Assets | 18 | 28 | 34 | 37 | 47 | 54 | 66 |
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ActivitiesCash from Operating | -0 | -1 | 1 | 5 | 4 | 2 |
| Cash from Investing | -2 | -6 | -3 | -4 | -2 | -7 |
| Cash from Financing | 3 | 7 | 2 | -2 | -1 | 8 |
| SummaryCapital Expenditure | — | — | — | — | — | — |
| Free Cash Flow | -2 | -5 | -4 | 3 | 2 | -2 |
| FCF Margin | — | — | — | — | — | — |
This looks cyclical, and we don't have enough quarters to establish a through-cycle earnings base. Valuing it off the current point in the cycle would be misleading.
WALPAR · CYCLICAL_UNMODELABLE
Guides on how to read this kind of business and the numbers that matter.